

1 0 <sup>T H</sup> A N N I V E R S A R Y



2 0 1 7

10<sup>th</sup>

PARIS  
HEPATOLOGY  
CONFERENCE

**30 & 31 January 2017**

**PARIS** - Palais des Congrès

---

**International Conference  
on the Management of Liver Diseases**

**Organised by Pr Patrick Marcellin,  
APHC**

**Organising Committee**

Michelle Martinot-Peignoux, Monelle Muntlak  
Hôpital Beaujon, APHP - INSERM CRI - Université Paris-Diderot

**Scientific Committee**

Marc Bourlière, Massimo Colombo, Rafael Esteban,  
Graham Foster, Michael Fried, Michael Manns

---



**[www.aphc.info](http://www.aphc.info)**



Follow us on Twitter: @PHC\_off #PHC2017



Dear Colleagues and Friends,

**We are pleased to welcome you at the 10th Paris Hepatology Conference (PHC).**

As usual, the meeting will provide state of the art information on the management of patients with liver disease by highly renowned international experts who will present the most recent results in the field and their clinical applications.

Thanks to the outstanding progress made in the treatment of hepatitis C with the new direct acting antiviral combinations, almost all these patients can now potentially be cured, including formerly «difficult to treat» patients (those with cirrhosis, co-infection with HIV and transplantation...). These combinations are well tolerated and highly effective with shorter treatment (high SVR rates after 12 weeks of treatment and a significant proportion of the population that responds after only 8 weeks).

Indeed, these advances raise the issue of how to facilitate access to treatment in more patients to reach the now realistic objective of eradicating hepatitis C. Eradication of HCV is now a dream shared by experts all over the world. To reach this goal a joint strategy is necessary involving different regions and countries. This will be debated during this PHC.

The goal of therapy in hepatitis B is now more ambitious: HBsAg loss and a clinical cure. Extensive research is focusing on viral eradication by developing new drugs with different mechanisms of action and different targets. Hopefully, within the next five years, safe combinations of potent antivirals, an effective immune-modulator and a drug interfering with protein synthesis or assembly will become available, with the ultimate goal of silencing or eradicating cccDNA.

For the first time this year, the PHC program includes outstanding experts in specific sessions and workshops to address unmet needs: NASH, HCC and end-stage liver disease, all difficult diseases with clinical issues commonly faced by all specialists.

As in previous PHCs, interactive discussions and specific lunch workshops have been organized to apply results to the management of real life patients. Indeed, the ultimate goal of the PHC 2017 is to review the most current knowledge and discuss their therapeutic applications with the most experienced experts to provide optimal therapies and the best chance of cure to as many patients as possible, worldwide.

We wish you a fruitful and pleasant meeting,

Amitiés,

**Professor Patrick Marcellin**  
President of the 10<sup>th</sup> Paris Hepatology Conference

08.30 - 08.40 **INTRODUCTION**

*Patrick Marcellin (France)*

08.40 - 10.00 **HEPATITIS C - SESSION 1**

*Chairs: Marc Bourlière (France), Rafael Esteban (Spain)*

- 08.40 ■ Universal Hepatitis C treatment: strategies for simplification *Tarik Asselah (France)*  
 08:55 ■ Policies for HCV elimination *Angelos Hatzakis (Greece)*  
 09.10 ■ Impact of therapy on the QOL *Geoffrey Dusheiko (UK)*  
 09:45 ■ Round table discussion

☕ 10.00 - 10.30 Coffee break

10.30 - 11.30 **HEPATITIS C - SESSION 2**

*Chairs: Nezam Afdhal (USA), Antonio Craxi (Italy)*

- 10.30 ■ Impact of therapy on metabolism and public health *Mitchell Shiffman (USA)*  
 10.45 ■ Special populations *Stefan Zeuzem (Germany)*  
 11.00 ■ Results in real life *Robert Flisiak (Poland)*  
 11.15 ■ Round table discussion

11.30 - 11.50 **CLINICAL CASE**

- Impact of therapy in a patient F1 *Eugene Schiff (USA)*

11.50 - 12.30 **STATE OF THE ART LECTURE & AWARD**

*Chair: Patrick Marcellin (France)*

- From HCV to HBV cure *Raymond Schinazi (USA)*

12.30 - 14.30 **LUNCH WORKSHOPS**

14.30 - 15.30 **NASH SESSION**

*Chairs: Arun Sanyal (USA), Lawrence Serfaty (France)*

- 14:30 ■ Epidemiology of NASH *Stefano Bellentani (Switzerland)*  
 14:45 ■ Pathology of NASH *Pierre Bedossa (France)*  
 15:00 ■ Lifestyle intervention in NASH *Vlad Ratziu (France)*  
 15:15 ■ Therapies in NASH *Arun Sanyal (USA)*

☕ 15:30 - 15:50 Coffee break

15.50 - 17.40 **AROUND THE WORLD TABLE: ACCESS TO THERAPY**

Introduction - *Massimo Colombo (Italy)*

**WESTERN COUNTRIES** *Chair: Massimo Colombo (Italy)*  
*Speakers: Maria Buti (Spain), Antonio Craxi (Italy), Graham Foster (UK), Michael Fried (USA), Victor de Ledinghen (France), Stefan Zeuzem (Germany)*

**OTHER COUNTRIES** *Chair: Michael Fried (USA)*  
*Speakers: Mustapha Benazzouz (Morocco), Robert Flisiak (Poland), Jinlin Hou (China), Vasily Isakov (Russia), Adriana Popescu (Romania), Raymundo Parana Filho (Brazil)*

17.40 - 18.00 **STATE OF THE ART LECTURE**

*Chair: Tarik Asselah (France)*

- The future of research on viral hepatitis *Charles Rice (USA)*

18.00 - 18.10 **TAKE HOME MESSAGES**

*Marc Bourlière (France)*

18.10 - 18.20 **CONCLUSION**

*Patrick Marcellin (France)*

19.30 Congress dinner



PARIS  
HEPATOLOGY  
CONFERENCE

Tuesday 31<sup>st</sup> January 2017

08.30 - 08.40 INTRODUCTION

*Patrick Marcellin (France)*

08.40 - 10.00 HEPATITIS B - SESSION 1

*Chairs: Ji Dong Jia (China), Georgios Papatheodoridis (Greece)*

08.40 ■ How to manage HBV patients in 2017?

*Georges Lau (Hong Kong)*

08.55 ■ When can we stop NUCs in patients with chronic hepatitis B?

*Seng-Gee Lim (Singapore)*

09.10 ■ Long term impact of antiviral therapy (NUCs)

*Pietro Lampertico (Italy)*

09.25 ■ Round table discussion

☕ 10.00 - 10.30 Coffee break

10.30 - 11.30 HEPATITIS B - SESSION 2

*Chairs: Michael Manns (Germany), Shiv Sarin (India)*

10.30 ■ New targets for HBV therapies

*Fabien Zoulim (France)*

10.45 ■ New anti-HBV strategies

*Edward Gane (New Zealand)*

11.00 ■ How to improve access to therapy for HBV patients?

*Michael Manns (Germany)*

11.15 ■ Round table discussion

11.30 - 12.45 END-STAGE LIVER DISEASE

*Chairs: Richard Moreau (France), Didier Samuel (France)*

11.30 ■ Prevention and treatment of variceal hemorrhage in 2017

*Jaime Bosh (Spain)*

11.45 ■ Why and how to assess renal function in cirrhosis

*Paolo Angeli (Italy)*

12.00 ■ Management of cholestatic diseases in 2017

*Ulrich Beuers (Netherlands)*

12.15 ■ The future of liver transplantation for viral hepatitis

*François Durand (France)*

12.30 ■ Round table discussion

12.45 - 14.30 LUNCH WORKSHOPS

14.30 - 14.50 TWO PROGRAMS OF HCV ERADICATION

*Chair: Graham Foster (UK)*

■ Follow-up of the Georgian and Egyptian programs

*Gamal Esmat (Egypt), Tengiz Tsertsvadze (Georgia)*

14.50 - 15.50 HCC SESSION

*Chairs: Jordi Bruix (Spain), Massimo Colombo (Italy)*

14.50 ■ The molecular road map of HCC

*Jessica Zucman Rossi (France)*

15.05 ■ The impact of anti HCV DAAs on HCC

*Jordi Bruix (Spain)*

15.20 ■ Reconsidering OLT to treat HCC in an era of donors shortage

*Didier Samuel (France)*

15.35 ■ Round table discussion

15.50 - 16.00 TAKE HOME MESSAGES

*Michael Fried (USA)*

16.00 - 16.10 CONCLUSION

*Patrick Marcellin (France)*

# PROGRAMME OF THE LUNCH WORKSHOPS

For people not registered to the lunch workshops, regular lunches are organised on Level 4

30<sup>th</sup> January from 12:30 to 14:30

## Room 252B

**Future therapies for HBV and HDV:  
What can we expect?**

*Chair:* Nezam Afdhal (USA)

*Speakers:* Raymundo Parana Filho (Brazil),  
Massimo Leviero (Italy)

## Room 251

**How to optimize treatment in G3 patients?**

*Chair:* Graham Foster (UK)

*Speakers:* Christophe Hezode (France),  
Mitchell Schiffman (USA)

## Room 242A

**DAAs treatment of patient with HIV-HCV co-infection**

*Chair:* Stanislas Pol (France)

*Speakers:* Geoffrey Dusheiko (UK),  
Yazdan Yazdanpanah (France)

## Room 241

**How to diagnose NASH?**

*Chair:* Vlad Ratziu (France)

*Speakers:* Pierre Bedossa (France),  
Ana Carolina Cardoso (Brazil)

## Room 242B

**The microbiome in liver diseases:  
Where are we?**

*Chair:* Arun Sanyal (USA)

*Speaker:* Gabriel Perlemuter (France)

## Room 243

**Treatment of HCC in real life**

*Chair:* Massimo Colombo (Italy)

*Speakers:* George Lau (Hong Kong),  
Vincent Di Martino (France)

## Room 252A

**Optimisation de la prise en charge d'un patient avec ascite**

*(French speaking lunch workshop)*

*Chairs:* Georges-Philippe Pageaux (France),  
Christian Trépo (France)

*Speakers:* Mustapha Benazzouz (Morocco),  
Philippe Mathurin (France)

31<sup>st</sup> January from 12:45 to 14:30

## Room 242A

**Treatment of transplanted HCV patients: when and how?**

*Chair:* Jordi Bruix (Spain)

*Speakers:* Maria Buti Ferret (Spain),  
Claire Francoz (France)

## Room 252B

**Need to assess HCV resistance to DAAs: is it useful and when?**

*Chair:* Edward Gane (New Zealand)

*Speakers:* Philippe Halfon (France),  
Stéphane Chevaliez (France)

## Room 242B

**Long term benefits and side effects of NUC therapy: where are we?**

*Chair:* Georgios Papatheodoridis (Greece)

*Speakers:* Petr Urbánek (Czech Republic),  
Vincent Leroy (France)

## Room 252A

**Optimal management of ascites**

*Chair:* Peter Ferenci (Austria)

*Speakers:* Dominique Thabut (France),  
Paolo Angeli (Italy)

## Room 251

**Management of autoimmune hepatitis**

*Chair:* Michael Manns (Germany)

*Speakers:* Vasily Isakov (Russia),  
Pierre-Emmanuel Rautou (France)

## Room 241

**How to manage patients with NASH?**

*Chair:* Lawrence Serfaty (France)

*Speakers:* Raluca Pais (France),  
Laurent Castera (France)

## Room 243

**Diagnostic et prise en charge d'un patient avec NASH**

*(French speaking lunch workshop)*

*Chairs:* Daniel Dhumeaux (France),  
Jean-François Cadranel (France)

*Speakers:* Denis Ouzan (France),  
Adriana Popescu (Romania)

# GENERAL INFORMATION

## CONFERENCE DATES AND VENUE

From Monday 30<sup>th</sup>  
to Tuesday 31<sup>st</sup> January 2017

At the "Palais des Congrès"  
2, place de la Porte Maillot  
75017 Paris – France

## CONFERENCE REGISTRATION DESK

30<sup>th</sup> & 31<sup>st</sup> January, from 7:30 am.  
Welcome desks are organised on level 2 of  
the Palais de Congrès in Foyer Bleu next to  
the Amphitheatre Bleu. You will be able to  
retrieve your access badge, congress bag  
and proceedings.

## CONGRESS OFFICE

Quadrature Santé / PHC 2017  
43 rue des Tilleuls  
92100 Boulogne-Billancourt  
Phone: +33 1 41 10 46 60  
Fax: +33 1 41 10 46 69  
Contact: [contact@aphc.info](mailto:contact@aphc.info)  
[www.aphc.info](http://www.aphc.info)

## CONGRESS HOTELS

**Hyatt Regency Paris Étoile**  
3 place du Général Koenig  
75017 Paris  
Tel: +33 (0) 1 40 68 12 34

**Méridien Etoile Hotel**  
81 boulevard Gouvion St-Cyr  
75 017 Paris  
Tel: +33 (0)1 40 68 34 34

## CONGRESS DINNER

Monday 30<sup>th</sup> January at the  
Pavillon Dauphine  
Place du Maréchal de Lattre de Tassigny,  
75116 Paris

Buses will leave from the Palais des  
Congrès from 7:00 p.m.  
Dress code : cocktail attire

## CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION

The "APHC" is accredited by the European  
Accreditation Council for Continuing  
Medical Education (EACCME) to provide  
the following CME activity for medical  
specialists.

The 10<sup>th</sup> Paris Hepatology Conference is  
designated for a maximum of (or "for up to")  
10 European CME credits (ECMEC).

## LIVER INTERNATIONAL

The PHC Liver International Supplement is  
available online at the following address:  
[http://onlinelibrary.wiley.com/doi/10.1111/  
liv.2017.37.issue-S1/issuetoc](http://onlinelibrary.wiley.com/doi/10.1111/liv.2017.37.issue-S1/issuetoc)

## LUNCHES

2 types of lunches are organised  
each day:

- *Lunch Workshops* (Level 2).

The number of seats is limited.

- *Regular lunches* are organised in Salon  
Arc en Ciel (Level 4).

## METRO and RER

The metro station (line 1) and RER station  
(line C) are located on level -1 of the  
Palais des Congrès: Porte Maillot station.  
The Conference will be held in  
Amphithéâtre Bleu on level 2.

## OFFICIAL LANGUAGE

The official language  
of the conference is English.

